US / Canada · Prescription Access · Last updated 6 November 2026
In brief: U.S. Customs and Border Protection (CBP) has extended a key compliance deadline affecting certain international mail shipments from October 22, 2026 to January 20, 2027. The 90-day extension postpones those Entry Type 13 requirements until January 20. A separate November 6 interim final rule introduces foreign-importer requirements with an earlier, delayed effective date, as explained below. The underlying Entry Type 13 requirements have not been cancelled. Since the extension was announced, the Canadian International Pharmacy Association (CIPA) has warned that it still expects major disruption to routine personal prescription shipments after January 20 unless the policy or its implementation changes.
Article update history
— Updated with CBP’s interim final rule on foreign importers of record, including its express Entry Type 13 applicability, CTPAT-validation requirements and limited broker-verification compliance relief. The rule takes effect 60 days after publication; the public-inspection version schedules publication for November 6, which would produce a January 5, 2027 effective date. It does not move the separate January 20 Entry Type 13 deadline or announce a blanket prohibition on pharmacy parcels.
— Updated following an operative October 22 CBP Federal Register notice temporarily allowing Entry Type 13 filings to be transmitted without complete electronic Partner Government Agency (PGA) data. The temporary measure eases one technical implementation requirement but does not change the January 20, 2027 compliance date, FDA admissibility rules or the importer-of-record requirements.
— Updated with SimplePills’ October 16 statement that it has adapted to the new requirements and expects US prescription shipping to continue after January 20. This represents an individual pharmacy’s operational position, not a change in CBP or FDA policy.
— Updated with CIPA’s operational warning about the expected effect on most routine personal prescription shipments after January 20.
— Updated following CBP’s October 14 announcement extending the relevant Entry Type 13 compliance deadline to January 20, 2027.
— First published.
The announcement is particularly relevant to Canadian and other international pharmacies that ship prescription medicines to customers in the United States. Several pharmacies had warned that the original October 22 deadline could disrupt their existing shipping models. CBP’s extension gives importers, brokers and logistics providers additional time to prepare, but it does not change existing FDA restrictions governing personal importation of prescription drugs.
Key Takeaways
- CBP has moved the relevant mandatory compliance date from October 22, 2026 to January 20, 2027.
- CBP says there will be no changes to international mail entry procedures before January 20, 2027 as a result of these requirements.
- From January 20, covered international postal shipments subject to certain trade duties or the jurisdiction of a Partner Government Agency (PGA) will require Entry Type 13 for informal entry; otherwise formal entry is required.
- Prescription medicines are regulated by the FDA, which is a Partner Government Agency for customs purposes.
- The extension postpones the customs deadline; it does not create a new legal right for Americans to import foreign prescription drugs.
- Entry Type 13 is already available on an optional basis during the transition period.
- Effective October 22, CBP temporarily modified the Entry Type 13 test so filings may be transmitted with or without complete electronic Partner Government Agency (PGA) data while filers work toward complete PGA submissions. CBP has not announced an end date for this temporary acceptance.
- CIPA now says its assessment remains that the arrangements used for most routine personal prescription orders will become unworkable after January 20 unless policy or implementation changes. This is an industry assessment, not a CBP or FDA announcement of a blanket prescription-import ban.
- CBP’s November 6 foreign-importer interim final rule expressly includes Entry Type 13. Once effective, a foreign importer of record must be CTPAT validated or use a CTPAT-validated licensed customs broker. Its 60-day effective-date formula would mean January 5, 2027 on the scheduled November 6 publication date; the separate January 20 Entry Type 13 deadline remains unchanged.
- CBP is separately proposing broader electronic entry and data requirements for most international mail packages, but that proposal is not yet the same as a final rule.
What Did CBP Change on October 14?
On October 14, 2026, CBP announced that it was extending the compliance date for new informal-entry procedures for international mail by 90 days, from October 22, 2026 to January 20, 2027.
According to CBP, the extension is intended to give importers, brokers and logistics providers more time to update their processes while reducing the risk of disruption to affected international postal shipments destined for the United States.
Most importantly for people concerned about an immediate October 22 disruption, CBP states that there are no changes to international mail entry procedures before January 20, 2027 as a result of the delayed requirements.
The extension does not withdraw the underlying rule. Instead, it moves the date on which mandatory use of the new Entry Type 13 process begins for the affected categories of informal international-mail entry.
What Happens on January 20, 2027?
Beginning January 20, CBP says international postal shipments subject to Section 201, 232 or 301 duties, or to the jurisdiction of a Partner Government Agency, will be required to use the new Entry Type 13 process when being entered informally. Otherwise, formal entry is required.
This matters for prescription medicines because imported human drugs are regulated by the U.S. Food and Drug Administration (FDA). FDA requirements therefore remain relevant to whether a prescription shipment can legally enter the United States.
The change concerns the customs-entry mechanism. It does not override FDA law or guarantee that a medicine submitted through Entry Type 13 will be admitted.
What Is Entry Type 13?
Entry Type 13 is a new electronic informal-entry process for international mail in CBP’s Automated Commercial Environment (ACE).
CBP’s Entry Type 13 test covers qualifying international-mail shipments valued at $2,500 or less and provides an electronic informal-entry pathway for eligible low-value postal shipments. Importantly, the test also provides a potential informal-entry pathway for certain low-value shipments subject to Partner Government Agency data requirements that would otherwise be ineligible for the interim postal informal-entry process.
CBP deployed the Entry Type 13 functionality to the production ACE environment on September 22, 2026. During the current transition period, CBP is encouraging filers to begin using the optional process so they can prepare for the January 20 mandatory deadline.
On October 22, CBP modified the Entry Type 13 test to temporarily accept filings even when they are not accompanied by complete electronic Partner Government Agency (PGA) data. CBP said the temporary measure is intended to let filers begin using Entry Type 13 while they work toward being able to submit all required PGA data electronically. CBP did not set an end date and said the conclusion of this temporary acceptance will be announced in a future Federal Register notice.
This is an operative CBP change, not a proposal. However, it relaxes one technical component of the Entry Type 13 test rather than removing the broader requirements. The notice still requires an eligible importer of record to file the Entry Type 13 data required by CBP electronically in ACE, and it does not change FDA rules governing whether a prescription medicine is admissible into the United States.
What Changed on November 6 for Foreign Importers of Record?
CBP’s “Heightened Requirements for Foreign Importers of Record” (document 2026-22735) is an interim final rule with a delayed effective date, not a proposed rule awaiting adoption. It is separate from the October 8 low-value-shipment proposal and the January 20 Entry Type 13 compliance deadline. The rule requests comments but does not make its requirements contingent on a later final rule.
Timing: The verified public-inspection PDF specifies effectiveness 60 days after Federal Register publication and schedules publication for November 6, 2026. That calculates to January 5, 2027 if publication occurs as scheduled. The PDF still contains date placeholders, so January 5 is a calculated date rather than a calendar date printed in that version. The same 60-day formula applies to the comment deadline. Nothing in this rule moves the separate January 20, 2027 mandatory Entry Type 13 date.
Scope: New 19 CFR 141.21 covers foreign importers of record entering merchandise for consumption through formal entry or informal entry requiring CBP Form 3461 or 7501, or their electronic equivalents. CBP expressly identifies informal entry types 11, 12 and 13, and all formal entry types in footnote 23. This is not a Canada-only or medicines-only rule. A foreign importer is an IOR that does not meet the new U.S.-IOR criteria in 19 CFR 110.2; foreign shipment origin alone does not determine the importer’s status.
CTPAT and brokers: A foreign IOR validated through the Customs Trade Partnership Against Terrorism (CTPAT) program may make entry if otherwise entitled to do so, or hire a licensed broker that need not itself be CTPAT validated. A foreign IOR that is not validated must designate a CTPAT-validated, licensed customs broker to make entry or act as IOR. The rule also requires a validated broker where the broker acts as IOR for a foreign principal on the power of attorney; the designated validated broker must act as IOR if that principal is not the owner or purchaser. A broker licence alone is therefore insufficient for an unvalidated foreign IOR. Application or initial CTPAT certification is not the same as completed validation, and using a validated broker does not confer CTPAT benefits on its client.
Limited broker compliance relief: The rule adds U.S.-IOR declarations, broker verification of clients’ U.S.-IOR qualifications and related recordkeeping. Eligible brokers may request delayed compliance with the new verification requirement in 19 CFR 111.29, explaining their need; the DATES provision calls for requests before the rule’s effective date. Approval is required, certain brokers facing enforcement action are ineligible, and approved brokers must demonstrate satisfactory progress and good-faith compliance to their current ability. CBP expects full broker compliance no later than May 6, 2027. This is not an automatic extension for every broker or a general postponement of the foreign-IOR CTPAT requirement.
Individual pharmacy parcels: The rule does not categorically abolish informal entry by foreign IORs; it preserves a route through a validated importer or validated broker. A qualifying U.S. IOR is not required by this rule to obtain CTPAT validation, although applicable entry requirements and the new declarations still apply. Its effect on a prescription parcel therefore depends on who is entitled to act as importer, the principal and broker arrangement, and the entry used. The text does not establish that every patient must obtain CTPAT validation or that every Canadian pharmacy parcel will stop. It does not change FDA drug-admissibility rules.
What Does the Extension Mean for Canadian Pharmacy Customers?
For customers worried that Canadian pharmacy shipments would suddenly face the new customs procedure on October 22, the immediate risk associated with that specific deadline has been postponed.
CBP’s announcement gives the businesses involved in international prescription fulfilment additional time to determine whether and how they can operate under the new electronic-entry requirements.
That does not mean nothing is changing. The new requirements are still scheduled to become mandatory for covered shipments on January 20, 2027, and pharmacies, postal operators, brokers and logistics providers may need to change their systems or processes before then.
Following the extension, the Canadian International Pharmacy Association (CIPA) said its assessment of the longer-term impact had not changed. CIPA says that unless the policy or its implementation changes before January 20, the arrangements currently used to deliver most personal prescription orders from licensed Canadian and international pharmacies to US patients will no longer be workable.
That conclusion is CIPA’s assessment of the operational consequences of the new requirements. It is not a CBP or FDA announcement that all Canadian prescription shipments will be prohibited after January 20.
Consumers should also remember that a customs-entry pathway and FDA admissibility are separate issues. Successfully filing an Entry Type 13 entry does not by itself make a foreign prescription drug lawful for personal importation.
Why Is CIPA Still Warning About January 20?
CIPA’s concern goes beyond whether Entry Type 13 technically exists as a filing option. The association says the practical problem involves the combination of customs-entry requirements, FDA requirements and who can take responsibility for prescription shipments entering through international postal systems.
According to CIPA, customs technology company Zonos acts as customs broker of record for nearly all major international postal systems, with many of those systems currently having no alternative broker performing that function. CIPA says this makes Zonos’s ability to process pharmaceutical entries particularly important for Canadian and other international pharmacies serving US customers.
CIPA says information it has received about implementation indicates that Zonos will not be able to act as importer of record for pharmaceutical shipments where the medicine is commercially available in the United States. CIPA argues that this would capture much of the ordinary market for personal prescription orders supplied to Americans by licensed pharmacies abroad.
CIPA also argues that simply filing an Entry Type 13 entry does not resolve the wider issue because the customs process still requires an eligible importer of record and other applicable entry requirements, while FDA requirements governing the medicine itself continue to apply. CBP’s October 22 modification temporarily allows Entry Type 13 filings without complete electronic PGA data, which may ease one implementation hurdle, but the notice does not remove the importer-of-record requirement or change FDA admissibility rules.
November 6 implications: The new foreign-IOR rule adds a concrete regulatory requirement to the importer-and-broker issue CIPA has highlighted. Our assessment is that arrangements relying on an unvalidated foreign pharmacy or fulfilment business as IOR may need a CTPAT-validated broker, while a qualifying U.S.-IOR arrangement requires a different analysis. Neither the October 22 PGA-data accommodation nor successful Entry Type 13 filing removes the new foreign-IOR conditions once effective. However, the rule does not establish the validation status, capacity or willingness of Zonos or any particular pharmacy’s broker, and it does not independently prove CIPA’s predicted market-wide disruption. CIPA’s earlier warning and SimplePills’ October 16 assurance below both predate this rule; neither should be read as a verified assessment of compliance with it.
This is an important distinction. The government’s published rules establish the customs procedures and FDA continues to determine drug admissibility. CIPA is drawing a further conclusion about how those requirements are likely to interact with the existing international-pharmacy shipping system. That operational conclusion should therefore not be presented as though CBP or FDA has formally announced that virtually all personal prescription imports will stop.
An individual pharmacy’s position: In its October 16, 2026 update, SimplePills says it has already adapted to the new requirements, does not plan to pause US shipping when the change takes effect on January 20, and currently expects customers to continue ordering and receiving medicines as usual.
This provides an operational counterpoint to CIPA’s broader warning and suggests that expectations may differ by pharmacy and shipping arrangement. It is SimplePills’ statement about its own service, not new government action, independent verification of its arrangements, or proof that the wider market will avoid disruption. It does not change CBP requirements or FDA admissibility rules, or guarantee that an individual shipment will be admitted.
Why Were Pharmacies and Patient Advocates Concerned About October 22?
Before CBP announced the extension, several Canadian and international pharmacy businesses warned US customers that the October 22 requirements could disrupt their existing shipping arrangements. Pharmacy and patient-access advocates also raised concerns about how the new procedures could affect Americans who obtain lower-cost prescription medicines from abroad.
PharmacyChecker urged the FDA to preserve its risk-based enforcement discretion for personal prescription drug imports in a September 17 statement responding to the new CBP procedures. The organization argued that additional information available at the border should help regulators distinguish medicines intended for an individual patient’s use from shipments that pose a genuine public-health risk. It also called on the FDA to provide clear guidance about the information needed to identify legitimate personal-use prescription drug shipments.
PharmacyChecker President Lucia Mueller warned that the new process could disrupt a route used by Americans seeking lower-cost medicines from licensed pharmacies abroad. PharmacyChecker nevertheless cautioned against treating the October 22 deadline as a blanket ban and advised accredited pharmacies not to encourage patients to stockpile medicines based on speculation about the rule changes.
NorthWestPharmacy used particularly strong language, saying it expected the changing CBP/FDA environment to block prescription shipments to Americans and advising customers to order before its own deadline.
Canadian Prescription Drugstore used more cautious wording, warning that the requirements were likely to cause delays or interruptions and potentially increase costs.
These warnings and advocacy efforts reflected concerns about the likely operational and patient-access impact of the new procedures. They were not themselves CBP or FDA announcements of a blanket prohibition, and CBP has not attributed its 90-day extension to any particular organization or advocacy effort. The extension reinforces the importance of distinguishing between the government’s confirmed requirements and predictions about how individual pharmacy businesses may respond to them.
Are Canadian Prescription Drugs Being Banned?
No new blanket ban on Canadian prescription-drug shipments was announced in CBP’s October 14 update.
Instead, CBP delayed the mandatory implementation of a new customs-entry process for affected international mail. From January 20, covered shipments will face the new Entry Type 13 or formal-entry requirements, while FDA law and admissibility requirements continue to apply independently.
The practical effect could nevertheless be significant. If a foreign pharmacy, postal operator, importer, broker or other filer cannot satisfy the applicable electronic filing and entry requirements, that may affect whether its existing shipping model remains workable. CBP’s October 22 modification temporarily eases the requirement for complete electronic PGA data, but it does not remove the other requirements that may affect individual shipping arrangements.
CIPA’s current position is stronger: it expects the arrangements used for most routine personal prescription orders to become unworkable after January 20 unless something changes. That prediction deserves attention because CIPA represents pharmacies directly involved in cross-border prescription fulfilment, but it remains an assessment of the expected operational impact rather than a new government prohibition.
Can Americans Legally Order Prescription Drugs From Canada?
The FDA’s position on personal importation remains restrictive. Its Personal Importation guidance states that, in most circumstances, it is illegal for individuals to import drugs into the United States for personal use when those foreign products are not approved by the FDA for US use and sale.
FDA does describe limited circumstances in which its personnel may consider exercising enforcement discretion. For a prescription drug used to treat a serious condition, relevant considerations can include whether effective treatment is unavailable domestically, whether the product is being commercialized or promoted to US residents, whether it presents an unreasonable risk, whether the consumer confirms that it is for personal use, and whether the quantity is generally no more than a three-month supply with appropriate physician or treatment information.
The FDA emphasizes that this is discretionary. Personal-importation policy does not give an individual a right or expectation that an unapproved drug will be admitted into the United States.
Does Entry Type 13 Make Prescription Importation Legal?
No. Entry Type 13 is a customs-entry mechanism, not an exemption from FDA drug law.
A shipment may be eligible for an informal customs entry while still being subject to FDA review. FDA can examine imported drug shipments and may detain or refuse products that appear to violate the Federal Food, Drug, and Cosmetic Act.
This distinction is important: the January 20 change concerns how qualifying international-mail shipments are entered and how required data are supplied to the US government. It does not automatically determine whether a particular prescription drug is admissible.
Will Every Canadian Pharmacy Shipment Be Stopped?
There is no current primary US government source stating that every Canadian pharmacy shipment will automatically be stopped on January 20, 2027.
FDA describes its international-mail review as risk-based. CBP refers FDA-regulated packages for FDA examination and admissibility decisions, and products appearing to violate FDA requirements may be detained or refused.
The new customs framework may make some shipments more difficult or expensive to process, and individual pharmacies may decide that continuing to serve US customers is no longer commercially or operationally practical. That is different from the government announcing that every Canadian prescription parcel is automatically prohibited.
However, CIPA now warns that the practical result could be much broader than the wording of the government rules alone suggests. Based on its assessment of the customs, FDA and broker requirements, CIPA says that without a policy or implementation change, Americans should expect most routine personal prescription orders mailed through the existing Canadian and international pharmacy system to face interruption after January 20.
Those two statements are not contradictory. CBP has not announced a universal ban on Canadian prescription parcels, while CIPA is predicting that the combined requirements will make the existing delivery model unworkable for much of the market. Whether pharmacies and logistics providers develop alternative compliant arrangements before January 20 remains an important issue to watch.
What Happens If a Prescription Shipment Is Detained?
FDA guidance explains that when an international-mail package appears to contain an FDA-regulated product that may violate US requirements, the agency can issue a Notice of FDA Action. The recipient or another responsible party may have an opportunity to provide information addressing the apparent violation.
If the information is sufficient to overcome the appearance of a violation, the product may be released. If not, FDA may refuse admission. Depending on the product and circumstances, a refused drug may be returned to the sender or may be subject to administrative destruction.
Does the Rule Apply Only to Canada?
No. The CBP requirements concern international postal shipments entering the United States and are not limited to Canada.
Canada is receiving particular attention because Canadian and international pharmacy businesses have long served US customers seeking lower prescription prices. The legal and regulatory status of an individual drug shipment still depends on the product, applicable FDA requirements and the circumstances of importation.
What Should People Using a Canadian Pharmacy Do Now?
If you currently receive prescription medicine through a Canadian or other international pharmacy, there is no need to interpret October 22 as the new mandatory Entry Type 13 deadline. CBP has moved that deadline to January 20, 2027 for the affected shipments.
Contact your pharmacy directly for information about its shipping plans. Different pharmacies may use different fulfilment locations, postal arrangements, carriers and filing processes, so the practical effect may not be identical for every provider.
If you are comparing providers, our guide explains how to verify a legitimate online pharmacy. Pharmacy verification and the rules governing US importation are separate checks.
You can also speak with the healthcare professional who prescribes your medicine about domestic alternatives, insurance coverage, manufacturer assistance programs, generic options or other appropriate ways to maintain continuity of treatment if your supply route changes. For an overview of these options, see our guide to Canadian pharmacy alternatives for US customers.
Do not change your dose, stop treatment or alter the amount of medicine you use without appropriate medical advice.
What Happens Next?
January 20, 2027 is now the key date to watch for the affected Entry Type 13 requirements. CBP is encouraging filers to use the optional Entry Type 13 process during the transition period so they can prepare for mandatory implementation.
The October 22 modification gives filers additional flexibility during that transition by temporarily allowing Entry Type 13 submissions without complete electronic PGA data. CBP says it will announce the end of this temporary acceptance in a future Federal Register notice, making that another implementation development to watch before January 20.
The separate foreign-importer rule adds an earlier timing issue: its effective date is 60 days after publication, calculated as January 5, 2027 if published on November 6 as scheduled. Pharmacies and logistics providers using foreign IORs therefore need to assess the CTPAT and broker requirements separately from their January 20 Entry Type 13 preparations. Any approved broker-verification delay ending no later than May 6 is narrower than a delay of the rule as a whole.
There is also a potentially broader change under consideration. On October 8, CBP proposed requiring new entry and data requirements for the informal entry of most international mail packages, except letters and flats. That is a proposed rule and should not be confused with a final requirement already applying to every international package.
MediSearcher will continue monitoring CBP, FDA and pharmacy-industry announcements and will update this page if the January deadline or the practical rules affecting prescription shipments change again.
CIPA’s warning adds an operational issue to watch: whether pharmacies, postal operators and customs brokers can establish workable arrangements before January 20, or whether policy or implementation changes address the obstacles CIPA has identified.
Bottom Line
The feared October 22, 2026 deadline has been postponed. CBP has extended mandatory implementation of the relevant Entry Type 13 requirements until January 20, 2027 and says international-mail entry procedures will not change under these requirements before then.
The extension gives pharmacies, importers, brokers and logistics providers another 90 days to prepare. It does not cancel the new customs framework, and it does not change the FDA’s existing restrictions on personal importation of prescription medicines.
CBP has since temporarily relaxed one part of the Entry Type 13 test by accepting filings without complete electronic PGA data. That may reduce one technical implementation barrier, but it does not resolve every issue identified by CIPA and does not change the importer-of-record requirement or FDA drug-admissibility rules.
For Americans using Canadian pharmacies, January 20 remains the mandatory Entry Type 13 milestone, alongside the separate foreign-IOR rule’s earlier effective-date timetable. The key question is no longer whether every shipment suddenly stops on October 22, but how pharmacies and their logistics partners adapt to Entry Type 13 before the new deadline.
CIPA now warns that, unless policy or implementation changes, the arrangements used for most routine personal prescription orders will become unworkable after January 20. That remains an industry assessment of the likely operational consequences, rather than a CBP or FDA announcement of a blanket prescription-import ban.
The November 6 interim final rule adds another requirement: foreign IORs must be CTPAT validated or use a validated licensed broker for covered entries, expressly including Entry Type 13. Its delayed effective date is 60 days after publication, calculated as January 5, 2027 if publication occurs on the scheduled November 6 date. It leaves the January 20 deadline intact. The practical impact on pharmacy shipping depends on the importer and broker arrangements; the rule does not announce a universal stop to individual prescription parcels or change FDA admissibility.
Sources and verification
This article was checked against current US government sources, including the October 14, 2026 CBP announcement extending the Entry Type 13 compliance date, the October 22 Federal Register notice modifying the Entry Type 13 test, and the November 6 foreign-importer interim final rule’s public-inspection text. The latter still contains publication-relative date placeholders; the January 5 date explained above is calculated from its scheduled November 6 publication.
- U.S. Customs and Border Protection / Federal Register — Heightened Requirements for Foreign Importers of Record (interim final rule; document 2026-22735; scheduled publication November 6, 2026; see DATES, section V and footnote 23, section VII, and new 19 CFR 110.2–110.3 and 141.21–141.22)
- U.S. Customs and Border Protection — International Mail Entry Type 13 mandatory implementation date extended to Jan. 20, 2027 (October 14, 2026)
- U.S. Customs and Border Protection — Implementation of Entry Type 13 Test in ACE for U.S. Mail Processing
- U.S. Customs and Border Protection / Federal Register — Indefinite Suspension of the De Minimis Exemption for Mail Shipments and New Postal Informal Entry Process
- U.S. Customs and Border Protection / Federal Register — Test of New Informal Entry Type for International Mail
- U.S. Customs and Border Protection / Federal Register — Modification of the Test of the New Electronic Informal Entry Process for Mail (October 22, 2026)
- U.S. Food and Drug Administration — Personal Importation
- U.S. Food and Drug Administration — Importing Prescription Drugs
- U.S. Food and Drug Administration — Shipment Admissibility
- U.S. Food and Drug Administration — International Mail Facilities
- PharmacyChecker — Urges FDA to Preserve Personal Prescription Drug Importation Under New CBP Rule (September 17, 2026)
- Canadian International Pharmacy Association — Customs Changes Expected to Halt Most Mailed Prescription Imports (October 20 update)
- SimplePills — U.S. Customs Moves Its October 22 Change to January 20, 2027 (October 16, 2026; individual pharmacy statement)
- NorthWestPharmacy — September 2026 customer warning
- Canadian Prescription Drugstore — Possible Disruption to Medication Supply
This article distinguishes between confirmed US government requirements and predictions about their operational impact. It is intended for general informational purposes and is not legal or medical advice.